news

(Reporter Xu Shiyu and Zhu Xiaona from People's Daily Health Client) Guangxi CDC announced on August 22 that the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention will conduct aHPVThe third phase clinical trial of the vaccine for men involves a domestically produced nine-valent vaccine, and 500 trial participants will be followed up over a six-year period. Many netizens are looking forward to men being able to get the human papillomavirus (HPV) vaccine in China.

On August 25, several clinical experts said in an interview with a reporter from the People's Daily Health Client that it is necessary for men to receive HPV vaccines from the perspective of collective immunity and disease prevention. After the indications are verified, the HPV vaccine for men will inevitably be allowed in China.

According to a study published in the International Journal of Cancer in 2017, human papillomavirus (HPV) is associated with a variety of human cancers. About 87% of all HPV-related cancers occur in women, and the other 13% occur in men. In fact, the United States, the United Kingdom, Australia, Japan, and my country's Hong Kong and Macau regions have already allowed men to receive the nine-valent HPV vaccine.

“Although men do not suffer fromCervical cancer, but they are the main carriers of the HPV virus and can also develop other diseases due to HPV infection. Male penile cancer, perianal cancer, oral cancer, genital warts, etc. are also related to HPV infection. "On August 25, Zou Shien, chief physician of gynecology at the Obstetrics and Gynecology Hospital Affiliated to Fudan University, told the People's Daily Health Client reporter that only when the vaccination coverage rate reaches a certain level and herd immunity is formed can more effective protection be achieved. If the indications of male HPV vaccine are approved for marketing in the future, men are also recommended to consider vaccination if the vaccine function is in sufficient supply.

"After men are infected with HPV, especially HPV16 and 18, the most common symptom is genital warts, which appear as small growths on the skin or mucous membranes. Some patients may experience itching, discomfort or pain in the external genitalia or perianal area." Professor Deng Liehua of the Dermatology Department of the First Affiliated Hospital of Jinan University told the reporter of the People's Daily Health Client that most HPV infections may have no obvious symptoms in the early or mild infection stages. Many men are not aware of the infection and may inadvertently spread the virus. Some high-risk HPV infections are associated with male genital cancers (such as penile cancer, anal cancer) and oropharyngeal cancer. Therefore, it is very important for high-risk groups or men with corresponding symptoms to regularly check for HPV.

Liu Jianhong, deputy chief physician of the Department of Gynecology at Hunan Women and Children's Hospital, said that she had seen many female patients in the clinic who were infected with HPV because of their male partners. Vaccination for men can not only protect themselves, but also protect women from infection. If sufficient supply can be guaranteed, the nine-valent HPV vaccine should also be given priority for male vaccination.

"However, from the perspective of priority, HPV vaccination should be given priority to girls aged 12-14 years old, and we hope to include HPV vaccination for this age group in the national immunization plan as soon as possible. So far, 141 countries and regions around the world have included HPV vaccination in their national immunization plans. Then consider women of other age groups, and finally consider HPV vaccination for men." On August 25, Professor of Peking Union Medical College, Chinese Academy of Medical SciencesWHOQiao Youlin, a member of the Global Cervical Cancer Elimination Expert Group, told the People's Daily Health Client reporter.

参考文献：[1]de Marted c, Pummer M, VignatJ et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. ImntJ Cance. 2017;141(4):664-670